Table 1

Baseline characteristics of patients with early inflammatory arthritis of non-crystal origin

RA

Non-RA persistent

Resolving

P


Number

8

14

14

Female (n)

4

6

6

NSa

Age (years)b,c

65.5 (55–73)

29.5 (23.5–61)

28.5 (21–45)

0.006d

RA versus non-RA persistent <0.05e

RA versus resolving <0.01e

Symptom duration (weeks)b,c

9 (6–9.5)

7.5 (2.5–11.5)

4 (2–8)

NSd

CRP (mg/l)b,c

31 (27.5–52.5)

67 (29–172.5)

24 (3.5–45)

NSd

RF ≥30 IU/ml (n)

7

0

2

<0.0001a

Anti-CCP antibodies ≥5 IU/ml (n)

7

0

1

<0.0001a

RF ≥30 IU/ml + Anti-CCP antibodies ≥5 IU/ml (n)

7

0

0

<0.0001a

Initial NSAID use (n)

7

6

8

NSa

Initial DMARD use (n)

0

0

0

NSa

Initial prednisolone use (n)

0

3

0

NSa

Joint aspirated (knee/ankle [n])

5/3

13/1

11/3

NSa


aχ2 test. bMedian. cInterquartile range. dKruskall–Wallis test. eWhere the medians were significantly different at the 5% level, Dunn's post-test was used to compare individual groups. CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; NS, not significant; NSAID, nonsteroidal antirheumatic drug; RA, rheumatoid arthritis; RF, rheumatoid factor.

Raza et al. Arthritis Research & Therapy 2005 7:R784-R795   doi:10.1186/ar1733

Open Data